Attached files
file | filename |
---|---|
10-K - 10-K - KalVista Pharmaceuticals, Inc. | kalv-10k_20180430.htm |
EX-32.2 - EX-32.2 - KalVista Pharmaceuticals, Inc. | kalv-ex322_130.htm |
EX-32.1 - EX-32.1 - KalVista Pharmaceuticals, Inc. | kalv-ex321_129.htm |
EX-31.2 - EX-31.2 - KalVista Pharmaceuticals, Inc. | kalv-ex312_132.htm |
EX-31.1 - EX-31.1 - KalVista Pharmaceuticals, Inc. | kalv-ex311_131.htm |
EX-23.2 - EX-23.2 - KalVista Pharmaceuticals, Inc. | kalv-ex232_127.htm |
EX-10.15 - EX-10.15 - KalVista Pharmaceuticals, Inc. | kalv-ex1015_183.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-2152815 and 333-217009 on Form S-3 and Registration Statement Nos. 333-203721, 333-215184, 333-216032 and 333-217008 each on Form S-8 of our report dated July 30, 2018, relating to the financial statements of KalVista Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2018.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
July 30, 2018